Legislative reports

The Oregon Prescription Drug Affordability Board approved 2025 PDAB Drug Review Report for sending to the Oregon Legislature in accordance with ORS 646A.697. The report includes:

• Overview of the 2025 review process
  
• Subset list of drug and insulin products reviewed in 2025
  
• Product-specific cost and affordability determination for Cosentyx, Trulicity, Vraylar, Lantus SoloStar
  
• Recommendations
  


ARCHIVED Legislative reports: The 2022, 2023, and 2024 reports are archived to conform with the rule on digital accessibility under Americans with Disabilities Act. It meets the following: 1. Created before April 24, 2026, or reproduces the contents of other physical media created before that date. 2. Is retained exclusively for reference, research, or recordkeeping. 3. Is not altered or updated after the date of archiving. 4. Is organized and stored in a dedicated area or areas clearly identified as being archived.

View 2025 Drug Review Report